Riise Gerdt, Magnusson Jesper, Larsson Hillevi, Hansson Lennart, Ingemansson Richard, Dellgren Göran
adjungerad professor, överläkare, Lungmedicin, Sahlgrenska universitetssjukhuset.
med dr, överläkare, Transplantationscentrum, Sahlgrenska universitetssjukhuset.
Lakartidningen. 2020 Aug 10;117:20015.
Lung transplantation is an accepted treatment for end stage lung diseases and performed at two national centers in Sweden - Gothenburg and Lund. Since the start in 1990 over 1 200 patients have been transplanted. The indications are severe progressive lung diseases with short expected survival or severe negative effects on daily life. There are several contraindications among which severe other organ disease, recent malignancy or psychiatric disease are most important. The most common causes for lung transplantation are chronic obstructive pulmonary disease (COPD), interstitial pulmonary disease, cystic fibrosis and pulmonary hypertension. Long term survival after 5 years is 63 %, and after 10 years 48 %, which is better than the results reported in the international registry (57 % and 36 % respectively). Lung transplantation is today a therapy for end stage pulmonary diseases with acceptable survival results. It is likely that the number of patients will increase in the future.
肺移植是终末期肺部疾病的一种公认治疗方法，在瑞典的两个国家中心——哥德堡和隆德进行。自1990年开展以来，已有超过1200名患者接受了移植手术。其适应症为预期生存期短或对日常生活有严重负面影响的严重进展性肺部疾病。存在多种禁忌症，其中严重的其他器官疾病、近期恶性肿瘤或精神疾病最为重要。肺移植最常见的病因是慢性阻塞性肺疾病（COPD）、间质性肺疾病、囊性纤维化和肺动脉高压。5年后的长期生存率为63%，10年后为48%，这优于国际登记处报告的结果（分别为57%和36%）。如今，肺移植是一种治疗终末期肺部疾病且生存结果可接受的疗法。未来患者数量可能会增加。
